
The 12th Clinical Trials in Oncology Europe conference wrapped up this week in Munich, and it was an excellent opportunity to connect with teams shaping the future of oncology research.
Over two days, we met researchers, clinicians, sponsors, CROs, and technology leaders who are working to improve how trials are designed and executed. The conversations reflected a clear theme: oncology development needs more precision in protocol design, stronger feasibility insights, and operational models that reduce risk from the very beginning.
We were pleased to join HEMEX and their team throughout the event, and grateful for the many discussions around how AI can support smarter protocol development, site selection, and data-driven decision making across oncology studies.
Thank you to everyone who took the time to meet with Rohit and learn more about Kitsa's work in advancing clinical trial intelligence. We look forward to continuing these conversations and collaborating with partners who share the goal of improving outcomes for oncology patients worldwide.
Discussions centered on the need for more precise, data-driven protocol development in oncology trials
Industry leaders emphasized operational models that reduce risk from the very beginning of study design
Collaborated with HEMEX throughout the event, exploring AI-supported protocol development and site selection
Connected with researchers, clinicians, sponsors, CROs, and technology leaders advancing oncology research




Keep exploring
Outsourcing in Clinical Trials DACH; Kitsa session and recap.
Screen failure in oncology trials can reach 50% in published audits. Learn how clinical trial software reduces manual screening burden and supports enrollment.
Kitsa at AWS Life Sciences — AI infrastructure for clinical development.
Kitsa at Bio-IT World — AI infrastructure for life sciences.